Oxford Biomedica (LON:OXB) Hits New 1-Year High – Time to Buy?

Oxford Biomedica plc (LON:OXB) hit a new 52-week high during mid-day trading on Friday . The stock traded as high as GBX 480 ($6.51) and last traded at GBX 475 ($6.44), with a volume of 420614 shares changing hands. The stock had previously closed at GBX 439.50 ($5.96).

Wall Street Analyst Weigh In

OXB has been the topic of several research reports. Peel Hunt reiterated a “buy” rating and issued a GBX 451 ($6.11) price target on shares of Oxford Biomedica in a research report on Friday, August 1st. JPMorgan Chase & Co. reduced their target price on Oxford Biomedica from GBX 490 ($6.64) to GBX 400 ($5.42) and set a “neutral” rating on the stock in a research note on Tuesday, July 15th.

Oxford Biomedica Trading Up 12.5%

The stock has a market cap of £525.66 million, a PE ratio of -3.67 and a beta of 1.09. The business has a 50-day moving average of GBX 372.59 and a 200 day moving average of GBX 336.93. The company has a debt-to-equity ratio of 166.48, a quick ratio of 1.67 and a current ratio of 2.35.

Insider Activity

In other news, insider Heather Preston purchased 11,389 shares of the stock in a transaction dated Tuesday, June 17th. The stock was acquired at an average cost of GBX 324 ($4.39) per share, for a total transaction of £36,900.36 ($50,014.04). 21.17% of the stock is owned by corporate insiders.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.